88 related articles for article (PubMed ID: 1979347)
21. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
Woll MM; Hueman MT; Ryan GB; Ioannides CG; Henderson CG; Sesterhan IA; Shrivasta S; McLeod DG; Moul JW; Peoples GE
Int J Oncol; 2004 Dec; 25(6):1769-80. PubMed ID: 15547716
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ
Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176
[TBL] [Abstract][Full Text] [Related]
23. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors.
Stancovski I; Schindler DG; Waks T; Yarden Y; Sela M; Eshhar Z
J Immunol; 1993 Dec; 151(11):6577-82. PubMed ID: 7902379
[TBL] [Abstract][Full Text] [Related]
24. In vivo properties of three human HER2/neu-expressing murine cell lines in immunocompetent mice.
Penichet ML; Challita PM; Shin SU; Sampogna SL; Rosenblatt JD; Morrison SL
Lab Anim Sci; 1999 Apr; 49(2):179-88. PubMed ID: 10331548
[TBL] [Abstract][Full Text] [Related]
25. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
26. The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase.
O'Hagan RC; Hassell JA
Oncogene; 1998 Jan; 16(3):301-10. PubMed ID: 9467955
[TBL] [Abstract][Full Text] [Related]
27. Antibodies and vaccines--hope or illusion?
Jäger D; Knuth A
Breast; 2005 Dec; 14(6):631-5. PubMed ID: 16242931
[TBL] [Abstract][Full Text] [Related]
28. Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study.
Stojadinovic A; Mittendorf EA; Holmes JP; Amin A; Hueman MT; Ponniah S; Peoples GE
Ann Surg Oncol; 2007 Dec; 14(12):3359-68. PubMed ID: 17906897
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
30. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.
Disis ML; Grabstein KH; Sleath PR; Cheever MA
Clin Cancer Res; 1999 Jun; 5(6):1289-97. PubMed ID: 10389911
[TBL] [Abstract][Full Text] [Related]
31. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
Altenschmidt U; Kahl R; Moritz D; Schnierle BS; Gerstmayer B; Wels W; Groner B
Clin Cancer Res; 1996 Jun; 2(6):1001-8. PubMed ID: 9816261
[TBL] [Abstract][Full Text] [Related]
32. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
33. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
Tuna M; Chavez-Reyes A; Tari AM
Oncogene; 2005 Feb; 24(9):1648-52. PubMed ID: 15674342
[TBL] [Abstract][Full Text] [Related]
34. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
Ross JS; Fletcher JA
Stem Cells; 1998; 16(6):413-28. PubMed ID: 9831867
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody.
Kern JA; Torney L; Weiner D; Gazdar A; Shepard HM; Fendly B
Am J Respir Cell Mol Biol; 1993 Oct; 9(4):448-54. PubMed ID: 8104437
[TBL] [Abstract][Full Text] [Related]
36. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
Hudziak RM; Lewis GD; Winget M; Fendly BM; Shepard HM; Ullrich A
Mol Cell Biol; 1989 Mar; 9(3):1165-72. PubMed ID: 2566907
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
Shepard HM; Lewis GD; Sarup JC; Fendly BM; Maneval D; Mordenti J; Figari I; Kotts CE; Palladino MA; Ullrich A
J Clin Immunol; 1991 May; 11(3):117-27. PubMed ID: 1679763
[TBL] [Abstract][Full Text] [Related]
38. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.
Lewis GD; Figari I; Fendly B; Wong WL; Carter P; Gorman C; Shepard HM
Cancer Immunol Immunother; 1993 Sep; 37(4):255-63. PubMed ID: 8102322
[TBL] [Abstract][Full Text] [Related]
39. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer.
Nunes RA; Harris LN
Clin Breast Cancer; 2002 Jun; 3(2):125-35; discussion 136-7. PubMed ID: 12123536
[TBL] [Abstract][Full Text] [Related]
40. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.
Tagliabue E; Centis F; Campiglio M; Mastroianni A; Martignone S; Pellegrini R; Casalini P; Lanzi C; Ménard S; Colnaghi MI
Int J Cancer; 1991 Apr; 47(6):933-7. PubMed ID: 1672668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
